Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 19/20 | 1.00 |
| ▸ | NQO2 | P16083 | 7/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075830 | 0.87 | MTNR1A (1.00) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL6077601 | 0.86 | MTNR1A (0.79) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL5342272 | 0.86 | MTNR1A (0.79) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL5336208 | 0.86 | MTNR1A (1.00) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL5338285 | 0.85 | MTNR1A (0.73) | MTNR1ANQO2MTNR1B | |
| SCHEMBL6075473 | 0.83 | MTNR1A (0.74) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL5339269 | 0.82 | NQO2 (1.00) | MTNR1ANQO2MTNR1B | |
| SCHEMBL7016328 | 0.81 | MTNR1A (1.00) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL6075596 | 0.81 | MTNR1A (0.71) | MTNR1ANQO2MTNR1BHTR2CHTR2B | |
| SCHEMBL27724020 | 0.81 | MTNR1A (0.73) | MTNR1ANQO2MTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | claimed |
| EP-3119406-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | Carmel-Haifa University Economic Corporation Ltd (IL) | 2017-01-25 | — | — | EP | claimed |
| WO-2015140799-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD (IL) | 2015-09-24 | — | — | WO | claimed |
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | claimed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| EP-1077928-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058496-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | claimed |
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2020-06-09 | — | — | US | disclosed |
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2020-06-09 | — | — | US | disclosed |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2019-04-25 | — | — | US | disclosed |
| US-10113171-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2018-10-30 | — | — | US | disclosed |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD. (IL) | 2017-03-23 | — | — | US | disclosed |
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
| EP-1077928-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058496-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676747-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, POLRMT | MTNR1A 309/4885NQO2 47/4885MTNR1B 494/4885 |
| US-10113171-B2 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, DHFR | MTNR1A 401/4885NQO2 32/4885MTNR1B 547/4885 |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885NQO2 492/4885MTNR1B 325/4885 |
| US-20190119684-A1 | METHODS FOR IMPROVING COGNITIVE FUNCTION VIA MODULATION OF QUINONE REDUCTASE 2 | GSTA2, NQO1, POLRMT | MTNR1A 309/4885NQO2 47/4885MTNR1B 494/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885NQO2 450/4885MTNR1B 340/4885 |
| US-20170081669-A1 | Methods for improving cognitive function via modulation of quinone reductase 2 | GSTA2, NQO1, DHFR | MTNR1A 401/4885NQO2 32/4885MTNR1B 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.